PCM
IDXX icon

Peregrine Capital Management’s Idexx Laboratories IDXX Stock Holding History

Peregrine Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-129,328
Closed -$15.2M – 249
2016
Q4 		$15.2M Sell
129,328
-32,984
-20% -$3.76M 0.39% 96
2016
Q3 		$18.3M Buy
+162,312
New +$17.1M 0.48% 73

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Peregrine Capital Management's IDXX Position: Q1 2017 in Review

Peregrine Capital Management sold out of Idexx Laboratories (IDXX) in Q1 2017, closing a stake of 129,328 shares — an estimated $15.2M sold.

Peregrine Capital Management first reported a position in IDXX in Q3 2016 and held it in 2 quarters. The position peaked at $18.3M in Q3 2016. 542 funds tracked by Wall St. Rank hold IDXX as of Q1 2017.

  • Peregrine Capital Management reported no remaining Idexx Laboratories position as of Q1 2017 after selling out during the quarter.
  • Peregrine Capital Management sold 129,328 Idexx Laboratories shares in Q1 2017, an estimated $15.2M.
  • Peregrine Capital Management first reported a position in Idexx Laboratories in Q3 2016 and held it in 2 quarters.
  • Peregrine Capital Management's Idexx Laboratories position peaked at $18.3M in Q3 2016.
  • 542 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2017.

Based on Peregrine Capital Management's 13F filing for Q1 2017, filed 7 Apr 2017.